Graham Capital Management L.P. Invests $321,000 in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Graham Capital Management L.P. bought a new position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 37,577 shares of the biopharmaceutical company's stock, valued at approximately $321,000.

Other hedge funds also recently added to or reduced their stakes in the company. Raymond James Financial Inc. acquired a new stake in Ocular Therapeutix during the 4th quarter worth approximately $1,722,000. Charles Schwab Investment Management Inc. raised its holdings in shares of Ocular Therapeutix by 1.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,131,485 shares of the biopharmaceutical company's stock valued at $9,663,000 after purchasing an additional 21,025 shares in the last quarter. Barclays PLC raised its holdings in shares of Ocular Therapeutix by 37.1% in the 3rd quarter. Barclays PLC now owns 511,522 shares of the biopharmaceutical company's stock valued at $4,451,000 after purchasing an additional 138,441 shares in the last quarter. RoundAngle Advisors LLC acquired a new stake in shares of Ocular Therapeutix in the 4th quarter valued at $1,695,000. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Ocular Therapeutix by 2,045.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,859 shares of the biopharmaceutical company's stock valued at $76,000 after purchasing an additional 8,446 shares in the last quarter. 59.21% of the stock is currently owned by institutional investors and hedge funds.

Ocular Therapeutix Stock Up 1.1%

Shares of NASDAQ OCUL traded up $0.08 during mid-day trading on Friday, reaching $7.30. The company had a trading volume of 1,627,989 shares, compared to its average volume of 1,398,772. Ocular Therapeutix, Inc. has a 52-week low of $4.79 and a 52-week high of $11.78. The company has a current ratio of 13.01, a quick ratio of 12.94 and a debt-to-equity ratio of 0.19. The stock has a market cap of $1.16 billion, a P/E ratio of -5.53 and a beta of 1.51. The firm has a 50 day simple moving average of $7.36 and a two-hundred day simple moving average of $8.04.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last issued its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.05). Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%. The business had revenue of $17.08 million for the quarter, compared to analysts' expectations of $16.89 million. Sell-side analysts predict that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on OCUL. Needham & Company LLC reduced their price objective on shares of Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating on the stock in a report on Tuesday, May 6th. William Blair began coverage on shares of Ocular Therapeutix in a report on Tuesday, April 8th. They issued an "outperform" rating on the stock. JMP Securities set a $19.00 price objective on shares of Ocular Therapeutix in a report on Tuesday, March 4th. Royal Bank of Canada assumed coverage on shares of Ocular Therapeutix in a research report on Tuesday, March 18th. They issued an "outperform" rating and a $17.00 target price on the stock. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $15.00 target price on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $16.25.

Insider Transactions at Ocular Therapeutix

In related news, insider Pravin Dugel sold 21,475 shares of the firm's stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $6.87, for a total value of $147,533.25. Following the completion of the sale, the insider now owns 3,520,318 shares in the company, valued at $24,184,584.66. This trade represents a 0.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Richard L. Md Lindstrom acquired 10,000 shares of Ocular Therapeutix stock in a transaction that occurred on Thursday, May 8th. The stock was bought at an average price of $6.96 per share, with a total value of $69,600.00. Following the purchase, the director now directly owns 172,704 shares of the company's stock, valued at approximately $1,202,019.84. This trade represents a 6.15% increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 2.30% of the company's stock.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.